• Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,681 common shares on June 30, 2026 at $70.
• He reported 9,756 common shares beneficially owned following the transaction.
• The filing was signed on July 2, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-295112), on July 02, 2026, and is solely responsible for the information contained therein.